1072-68-0

Basic information

• Product Name: 1,4-DIMETHYLPYRAZOLE
• Synonyms: 1,4-DIMETHYL-1H-PYRAZOLE;1,4-DIMETHYLPYRAZOLE;Pyrazole, 1,4-dimethyl-;1,4-Dimethyl-1H-pyrazol
• CAS NO: 1072-68-0
• Molecular Formula: C₅H₈N₂
• Molecular Weight: 96.13
• EINECS: 1312995-182-4
• Mol File: 1072-68-0.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 145.592 °C at 760 mmHg
• Flash Point: 41.853 °C
• Appearance: /
• Density: 0.983 g/cm³
• Vapor Pressure: 6.09mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: Room temperature.
• PKA: 2.80±0.10(Predicted)
• CAS DataBase Reference: 1,4-DIMETHYLPYRAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DIMETHYLPYRAZOLE(1072-68-0)
• EPA Substance Registry System: 1,4-DIMETHYLPYRAZOLE(1072-68-0)

Safety Data

• Hazardous Substances Data: 1072-68-0(Hazardous Substances Data)

Usage

Uses

Used in Chemical Industry:
1,4-Dimethylpyrazole is used as a corrosion inhibitor for its ability to protect materials from degradation in corrosive environments, thereby extending their service life and reducing maintenance costs.
Used in Polymer Industry:
1,4-Dimethylpyrazole serves as a stabilizer for polymers, enhancing their resistance to degradation from environmental factors such as heat, light, and oxygen, which in turn improves the polymers' longevity and performance.
Used in Pharmaceutical Industry:
1,4-Dimethylpyrazole is used as a reagent in organic synthesis, contributing to the development of new pharmaceutical compounds and facilitating the synthesis of complex organic molecules.
Used in Research and Development:
1,4-Dimethylpyrazole is utilized in the investigation of its potential as a pharmaceutical agent, particularly as an inhibitor of cytochrome P450 enzymes, which are involved in the metabolism of various drugs and other substances in the body. This application could lead to advancements in drug interactions and efficacy studies.

InChI:InChI=1/C5H8N2/c1-5-3-6-7(2)4-5/h3-4H,1-2H3

Upstream product

• 7554-65-6 4-methyl-1H-pyrazole 
• 56-23-5 tetrachloromethane 
• 160886-90-8 2,4-dimethyl-2H-pyrazole-3-carbonyl chloride 
• 74-88-4 methyl iodide 
• 123-91-1 1,4-dioxane 
• 102-85-2 tri-n-butyl phosphite 
• 10602-37-6 1,1,3,3-tetraethoxy-2-methyl-propane 
• 7339-53-9 methyl hydrazine hydrochloride 

Downstream Products

• 1174834-52-6 1,4-dimethyl-1H-pyrazole-5-sulfonyl chloride 
• 4054-67-5 3,3',5,5'-tetramethyl-1H,1'H-4,4'-bipyrazole 
• 1383422-53-4 3-methyl-N-[(4-methyl-1H-pyrazol-1-yl)methyl]benzamide 
• 1047645-44-2 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(1,4-dimethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride 
• 1047645-51-1 5-chloro-4-(1,4-dimethyl-1H-pyrazol-5-yl)-N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-2-thiophenecarboxamide 
• 1047645-42-0 4-(1,4-dimethyl-1H-pyrazol-5-yl)-N-((1S)-2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-2-thiophenecarboxamide 
• 1047644-57-4 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-5-chloro-4-(1,4-dimethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1047644-52-9 N-((1S)-2-amino-1-{[2-(trifluoromethyl)phenyl]methyl}ethyl)-4-(1,4-dimethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide 
• 1395443-04-5 3-iodo-1,4-dimethyl-1H-pyrazole 
• 1609470-39-4 C₁₂H₁₂F₂N₂O₂S 
• 1420531-80-1 (2-bromo-5-(trifluoromethyl)phenyl)(1,4-dimethyl-1H-pyrazol-5-yl)methanol 
• 1420531-85-6 ethyl 2-(3-(2-((1,4-dimethyl-1H-pyrazol-5-yl)methyl)-4-(trifluoromethyl)phenyl)-5-fluoro-1H-indol-1-yl)acetate 
• 1420531-84-5 3-(2-((1,4-dimethyl-1H-pyrazol-5-yl)methyl)-4-(trifluoromethyl)phenyl)-5-fluoro-1H-indole 
• 1420531-83-4 3-(2-((1,4-dimethyl-1H-pyrazol-5-yl)methyl)-4-(trifluoromethyl)phenyl)-5-fluoro-1-tosyl-1H-indole 

Relevant articles and documents

NEW CRTH2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

NEW CRTh2 ANTAGONISTS

The present invention relates to compounds of formula (I), to the process for preparing such compounds and to their use in the treatment of a pathological condition or disease susceptible to amelioration by CRTh2 antagonist activity.

Amino-Containing Compounds Which Inhibit Memapsin 2 Beta-Secretase Activity and Methods of Use Thereof

The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease.

BICYCLIC COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF

The present invention provides bicyclic beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer’s disease.

Nitropyrazoles: XII. Transformations of the 4-methyl group in 1,4-dimethyl-3,5-dinitropyrazole and cyclization of the transformation products

A preparative procedure for the synthesis of 1,4-dimethyl-3,5- dinitropyrazole by nitration of 1,4-dimethylpyrazole was developed. The reaction of 1,4-dimethyl-3,5-dinitropyrazole with dimethoxymethyl-(dimethyl)amine (N,N-dimethylformamide dimethyl acetal) gave (E)-N,N-dimethyl-2-(1-methyl-3,5- dinitropyrazol-4-yl)ethenylamine. Acid hydrolysis of the latter afforded (1-methyl-3,5-dinitropyrazol-4-yl)acetaldehyde, and the reaction with sodium nitrite in hydrochloric acid led to formation of 2-hydroxymino-2-(1-methyl-3,5- dinitropyrazol-4-yl)acetaldehyde. The corresponding O-methyloxime and phenylhydrazone reacted with K2CO3 to give 6-methyl-4-nitropyrazolo[4,3-d]isoxazole-3-carbaldehyde O-methyloxime and 1-methyl-3-nitro-4-(2-phenyl-2H-1,2,3-triazol-4-yl)pyrazol-5-ol, respectively. Treatment of (1-methyl-3,5-dinitropyrazol-4-yl)-acetaldehyde with benzenediazonium chloride gave (1-methyl-3,5-dinitropyrazol-4-yl)acetaldehyde phenylhydrazone which underwent intramolecular cyclization with replacement of the 5-nitro group by the action of K2CO3 in acetonitrile; in the reaction with K2CO3 in ethanol, the 5-nitro group was replaced by ethoxy.

Method for producing 1 substituted 5-chloro-4 methly pyrazoles

The present invention relates to a process for preparing 1-substituted 5-chloro-4-methylpyrazoles of the general formula I with the meaning for R stated in claim 1, in which a 4-methylpyrazole of the formula II is reacted with chlorine, the resulting mixture of monochlorinated and dichlorinated product is fractionated by distillation, and subsequently the dichlorinated compound is dehalogenated to compound II and returned to the reaction with chlorine.

N-alkylation method of pyrazole

An N-alkylation method of pyrazole in which (III) is produced from (I) and (II), which is characterized by using a crystalline aluminosilicate or a crystalline aluminophosphate as a catalyst: STR1 wherein each of R1, R2 and R3 represents hydrogen, alkyl, alkenyl or phenyl, R represents alkyl and Q represents hydrogen, alkyl or COOR. This is an industrially markedly useful method, because (III) can be obtained with a high yield under mild reaction conditions, and by-products including salts are not at all formed.

Process for preparing N-substituted pyrazoles

A process for the preparation of an N-alkyl- or N-phenylalkyl-substituted pyrazole I by reacting the corresponding N-unsubstituted pyrazole II with an alcohol III of the formula R1 --OH where R1 is the same alkyl or phenylalkyl group to be added to the unsubstituted nitrogen group --NH-- of the pyrazole reactant. Both of the reactants, i.e. the pyrazole II and alcohol III compounds, are catalytically reacted in the liquid phase in a molar ratio of from 0.001:1 to 1:1, at temperatures of 50°-400° C. and under a subatmosheric pressure of from 0.8 bar up to a superatmospheric pressure of 250 bar. The catalyst required for this liquid phase reaction is selected as being at least one or more non-heterogeneous acid catalysts, their alkyl esters or their acid anhydrides.

N-alkylation of heterocyclic, aromatic amines

A process for producing a heterocyclic tertiary amine of the formula (III): STR1 wherein A is a nitrogen atom or C-R5, B is a nitrogen atom or C-R6, is a single bond or a double bond, and each of R1, R2, R3, R4, R5 and R6 which may be the same or different, is a hydrogen atom, an acyl group, a halogen atom, a cyano group, etc., provided that two of R1, R2, R3 and R4 may together form a 3-membered, 4-membered, 5-membered or 6-membered aliphatic ring, a heterocyclic rig or aromatic ring, and R7 is a C1-6 alkyl group which may be substituted, etc., which process comprises reacting a heterocyclic secondary amine of the formula (I): STR2 wherein A, B, , R1, R2, R3 and R4 are as defined above, with an alkylating agent of the formula (II): wherein R7 is as defined above, and X is a hydroxyl group, a halogen atom, a OSO3 R7 group, a OSO2 R7 group, a OCO2 R7 group, a OCOR7 group, a OP(O)(OR7) group, a OP(O)O(R7)2 group or an amino group, in the presence of a catalyst of Group VIII of the Periodic Table.